Full View

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

CS Ujjani, SH Jung, B Pitcher, P Martin… - Blood, The Journal …, 2016 - ashpublications.org
Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted
therapies are being investigated as potentially more efficacious and tolerable alternatives for …
被引用次数：57 相关文章

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

CS Ujjani, SH Jung, B Pitcher, P Martin, SI Park… - Blood, 2016 - cdr.lib.unc.edu
Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted
therapies are being investigated as potentially more efficacious and tolerable alternatives for …

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

CS Ujjani, SH Jung, B Pitcher, P Martin, SI Park… - …, 2016 - ohiostate.elsevierpure.com
Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted
therapies are being investigated as potentially more efficacious and tolerable alternatives for …

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

CS Ujjani, SH Jung, B Pitcher, P Martin, SI Park… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted
therapies are being investigated as potentially more efficacious and tolerable alternatives for …

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.

CS Ujjani, SH Jung, B Pitcher, P Martin, SI Park… - Blood, 2016 - europepmc.org
Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted
therapies are being investigated as potentially more efficacious and tolerable alternatives for …
[HTML] sciencedirect.com

[HTML][HTML] Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

CS Ujjani, SH Jung, B Pitcher, P Martin, SI Park… - Blood, 2016 - Elsevier
Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted
therapies are being investigated as potentially more efficacious and tolerable alternatives for …

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

CS Ujjani, SH Jung, B Pitcher, P Martin, SI Park… - Blood, 2016 - cir.nii.ac.jp
抄録< jats: title> Key Points</jats: title>< jats: p> The combination of rituximab, lenalidomide,
and ibrutinib is associated with a high incidence of rash in follicular lymphoma (all grades …
[PDF] core.ac.uk

[PDF][PDF] Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

CS Ujjani, SH Jung, B Pitcher, P Martin, SI Park… - Blood, 2016 - core.ac.uk
The standard approach for the treatment of advanced-stage follicular lymphoma, the most
common of the indolent non-Hodgkin lymphomas (NHL), has traditionally consisted of …
[HTML] nih.gov

[HTML][HTML] Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

CS Ujjani, SH Jung, B Pitcher, P Martin, SI Park… - Blood, 2016 - ncbi.nlm.nih.gov
Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted
therapies are being investigated as potentially more efficacious and tolerable alternatives for …

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

CS Ujjani, SH Jung, B Pitcher, P Martin, SI Park… - Blood, 2016 - profiles.wustl.edu
Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted
therapies are being investigated as potentially more efficacious and tolerable alternatives for …